💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Marinus Pharmaceuticals, Inc. (MRNS)
« Back to company indexMRNS Chatter Timeline
Stock Ticker for MRNS
Most Active Tweeters for MRNS
| User | Tweets |
|---|---|
| @MysteriousMole1 | 16 |
| @FlashAlert_me | 11 |
| @_B_I_O_T_E_C_H_ | 9 |
| @InsiderAlerts4U | 6 |
| @Tickeron | 4 |
Recent Tweets for MRNS
 |
@TradingAloha #idea $MRNS The move is getting close. High compression squeeze with momentum trending upward. Looking for a fast p… https://t.co/MxVMGWZ0UG January 20th 2021, 5:01am |
 |
@InsiderAlerts4U $MRNS: New Insider Filing on MARINUS PHARMACEUTICALS INC's Director CHARLES AUSTIN: https://t.co/2oXgd228QR January 20th 2021, 5:01am |
|
@InsiderAlerts4U $MRNS: New Insider Filing on MARINUS PHARMACEUTICALS INC's Director ELAN EZICKSON: https://t.co/2FH4iYGeRt January 20th 2021, 4:01am |
|
@InsiderAlerts4U $MRNS: New Insider Filing on MARINUS PHARMACEUTICALS INC's Chief Medical Officer JOSEPH HULIHAN: https://t.co/x0ssHO4PP2 January 20th 2021, 4:01am |
|
@InsiderAlerts4U $MRNS: New Insider Filing on MARINUS PHARMACEUTICALS INC's VP Gen Counsel and Corp Sec. MARTHA E MANNING: https://t.co/GeoOhSkfGb January 20th 2021, 3:01am |
|
@InsiderAlerts4U $MRNS: New Insider Filing on MARINUS PHARMACEUTICALS INC's Chief Executive Officer SCOTT BRAUNSTEIN: https://t.co/tFsOZpKUIB January 20th 2021, 3:01am |
|
@InsiderAlerts4U $MRNS: New Insider Filing on MARINUS PHARMACEUTICALS INC's Director ENRIQUE J. CARRAZANA: https://t.co/FKVetpiiZM January 20th 2021, 1:01am |
 |
@StockTexts $MRNS Marinus Pharmaceuticals, Inc. SEC Filing: Form 4 https://t.co/TyBRU4asIe January 20th 2021, 1:01am |
 |
@FlashAlert_me $MRNS [15s. delayed] filed SEC form 4: Director DOUGHERTY MICHAEL R: Transacted Derivative Securities on 2021-01-1… https://t.co/2byRISa3zQ January 20th 2021, 1:01am |
|
@FlashAlert_me $MRNS [15s. delayed] filed SEC form 4: Director Carrazana Enrique J.: Transacted Derivative Securities on 2021-01-… https://t.co/qrJ6Pj7bdZ January 20th 2021, 1:01am |
|
@FlashAlert_me $MRNS [15s. delayed] filed SEC form 4: Chief Executive Officer Braunstein Scott: Transacted Derivative Securities… https://t.co/V2l5S6OdQJ January 20th 2021, 1:01am |
|
@FlashAlert_me $MRNS [15s. delayed] filed SEC form 4: Director Austin Charles: Transacted Derivative Securities on 2021-01-15. https://t.co/YoFvqots65 January 20th 2021, 1:01am |
|
@FlashAlert_me $MRNS [15s. delayed] filed SEC form 4: Director Ezickson Elan: Transacted Derivative Securities on 2021-01-15. https://t.co/M58ilGotyS January 20th 2021, 1:01am |
|
@StockTexts $MRNS Marinus Pharmaceuticals, Inc. SEC Filing: Form 4 https://t.co/cTQKOZm6OR January 20th 2021, 1:01am |
|
@FlashAlert_me $MRNS [15s. delayed] filed SEC form 4: Director Fischer Seth H. Z.: Transacted Derivative Securities on 2021-01-15… https://t.co/plvIwhM8fk January 20th 2021, 1:01am |
|
@FlashAlert_me $MRNS [15s. delayed] filed SEC form 4: Chief Medical Officer Hulihan Joseph: Transacted Derivative Securities on 2… https://t.co/GWaLQ7bpAG January 20th 2021, 1:01am |
|
@FlashAlert_me $MRNS [15s. delayed] filed SEC form 4: VP Gen Counsel and Corp Sec. MANNING MARTHA E: Transacted Derivative Securi… https://t.co/nT2dfRSztp January 20th 2021, 1:01am |
|
@FlashAlert_me $MRNS [15s. delayed] filed SEC form 4: Director MAYLEBEN TIMOTHY M: Transacted Derivative Securities on 2021-01-15… https://t.co/Rn9lz8dkpn January 20th 2021, 1:01am |
 |
@intratio $MRNS https://t.co/OUo56XurEF Marinus Pharmaceuticals Inc Our advanced model is predicting that this companie s sto… https://t.co/aouA6I6Dad January 19th 2021, 3:01am |
 |
@QuantchaIdeas StockTwits Trending Alert: Trading recent interest in MARINUS PHARMACEUTICALS INC. $MRNS https://t.co/vka4Qqu4Gh January 16th 2021, 4:01pm |
 |
@SwingTradeBot Recent $MRNS technical alerts: Non-ADX 1,2,3,4 Bearish plus 9 more alerts... https://t.co/lrDrafI7sh January 16th 2021, 4:01pm |
 |
@ML_Tweet_Bot RT @intratio: $MRNS https://t.co/OUo56XurEF Marinus Pharmaceuticals Inc The machine learning model concludes this equity value will go sout… January 15th 2021, 11:01pm |
|
@intratio $MRNS https://t.co/OUo56XurEF Marinus Pharmaceuticals Inc The machine learning model concludes this equity value wi… https://t.co/24a9awy8EL January 15th 2021, 11:01pm |
 |
@aaadhikari Added $MRNS 12.6 January 15th 2021, 3:01pm |
 |
@RolandoAMoreno RT @MysteriousMole1: $MRNS at JPM: literature suggests +/- 10% likelihood of response to additional AED in the patients enrolled in the PhI… January 15th 2021, 12:01am |
 |
@_B_I_O_T_E_C_H_ RT @MysteriousMole1: $MRNS Q&A cntd: - physician interactions at AED: success in CDD, which is extremely refractory, stokes interest to run… January 14th 2021, 10:01pm |
|
@_B_I_O_T_E_C_H_ RT @MysteriousMole1: $MRNS Q&A cntd: - On BARDA partnership: agency interested in intramuscular formulation of GNX for use in the battlefie… January 14th 2021, 9:01pm |
|
@_B_I_O_T_E_C_H_ RT @MysteriousMole1: $MRNS Q&A cntd: - Q on IV franchise, A: physician enthusiasm helps get the PhIII in RSE off the ground despite the pan… January 14th 2021, 9:01pm |
 |
@MysteriousMole1 $MRNS Q&A cntd: - physician interactions at AED: success in CDD, which is extremely refractory, stokes interest to… https://t.co/QI2x6GRcVR January 14th 2021, 9:01pm |
|
@MysteriousMole1 $MRNS Q&A cntd: - based on strategic discussions, expect to add to balance sheet in non-dilutive way by mid-2021 -… https://t.co/gd2IwcMw6s January 14th 2021, 9:01pm |
|
@MysteriousMole1 $MRNS Q&A cntd: - On BARDA partnership: agency interested in intramuscular formulation of GNX for use in the battle… https://t.co/88pofPVnnW January 14th 2021, 9:01pm |
|
@MysteriousMole1 $MRNS Q&A cntd: - Q on IV franchise, A: physician enthusiasm helps get the PhIII in RSE off the ground despite the… https://t.co/SC2vAwp3Yw January 14th 2021, 9:01pm |
|
@MysteriousMole1 $MRNS Q&A: - on NDA submission: FDA confirmation of sufficiency of single PhIII trial addresses key concern of both… https://t.co/dsCA4tdQ3c January 14th 2021, 9:01pm |
|
@MysteriousMole1 $MRNS - On PCDH19: episodic cluster seizures; ongoing double-blind study to deliver top-line data before end of Q1 (!!!) January 14th 2021, 9:01pm |
|
@MysteriousMole1 $MRNS - given that TSC trial replicates CDD PhIII TID dosing, and presents with similar allo-s disruption, Co is co… https://t.co/XX6YLuOnSx January 14th 2021, 9:01pm |
|
@MysteriousMole1 $MRNS - next gen formulations will open up large swathes of new applications beyond refractory epilepsy - on the o… https://t.co/bO0bEhs7UF January 14th 2021, 8:01pm |
|
@MysteriousMole1 $MRNS future of the franchise: - when dosed TID in CDD, 70% of patients had excellent absorption of GNX - Co worki… https://t.co/Jklr3qMKy6 January 14th 2021, 8:01pm |
|
@MysteriousMole1 $MRNS despite frailty of CDD patients, oral GNX exhibited no new safety signals - very clean drug Duration of effi… https://t.co/yJPEdwbhYw January 14th 2021, 8:01pm |
|
@MysteriousMole1 $MRNS recap of CDD prevalence and results of 1st ever, global PhIII (n=100) which achieved primary endpoint with hi… https://t.co/dtGlBVqMGv January 14th 2021, 8:01pm |
|
@MysteriousMole1 $MRNS at JPM: literature suggests +/- 10% likelihood of response to additional AED in the patients enrolled in the… https://t.co/jTGBoddt4F January 14th 2021, 8:01pm |
 |
@DuarteSatirico RT @semodough: CANT $MRNS PT $27 FDA gave positive response on filing of an NDA based on one Ph3 trial in CDKL5 deficiency disorder (CDD),… January 14th 2021, 12:01pm |
 |
@semodough CANT $MRNS PT $27 FDA gave positive response on filing of an NDA based on one Ph3 trial in CDKL5 deficiency disorde… https://t.co/b5oP1mFETc January 14th 2021, 12:01pm |
 |
@rmacmillan310 $MRNS price movement 11.04 % https://t.co/aELNYugChp January 14th 2021, 8:01am |
 |
@BioWino $mrns $kura.. complete clownshow after they offered those names. banks are just giving stock to anyone apparently January 14th 2021, 1:01am |
 |
@MaisaCorp $MRNS FDA supporting the filing of a new drug application for the use of the company's oral ganaxolone drug candida… https://t.co/GOvi5VYjVo January 13th 2021, 9:01pm |
|
@MysteriousMole1 RT @semodough: Baird $MRNS Key catalyst In 1H21, mgt readout top-line data from Phase 2 Violet study oral ganaxolone in PCDH19-related epi… January 13th 2021, 9:01pm |
 |
@StockNewsNow $MRNS Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for… https://t.co/YU4jFeWij1 January 13th 2021, 8:01pm |
|
@semodough Baird $MRNS Key catalyst In 1H21, mgt readout top-line data from Phase 2 Violet study oral ganaxolone in PCDH19-re… https://t.co/jcmSPij3G6 January 13th 2021, 7:01pm |
 |
@InvestrClouseau RT @_B_I_O_T_E_C_H_: $MRNS Marinus Pharmaceuticals Receives Positive Response From #FDA On Sufficiency Of One Phase 3 Clinical Trial For Fi… January 13th 2021, 3:01pm |
 |
@MarcJacksonLA $MRNS Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for… https://t.co/GOPqfIfsv2 January 13th 2021, 3:01pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
- ✓ Patent Expirations and Generic Entry
- ✓ 505(b)(2) & Biosimilars
- ✓ Insightful Articles and Case Studies
- ✓ Patent Litigation & Challenges
- ✓ Industry Trends
